Neurorehabilitation for Parkinson's (NCT07010328)
Reduce forward and sideways leaning
- Trial ID
- NCT07010328
- Official Title
- Efficacy of Integrating Artificial Intelligence Solutions in Rehabilitation in Postural Trunk Disorders in Parkinson's Disease.
- Goal
- Reduce forward and sideways leaning
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Parkinson Disease, Physical Inactivity, Physical Disability, Pisa Syndrome
- Interventions
- Neurorehabilitation, AI-based home rehabilitation for postural disorders
Summary For Families
The goal is to reduce abnormal forward or sideways bending of the trunk, namely camptocormia and Pisa syndrome, to improve posture, balance and daily function in people with Parkinson's. The approach uses an AI-guided home neurorehabilitation program that tracks trunk angles with sensors or camera-based analysis, gives real-time feedback, and personalizes strengthening, stretching and posture-training exercises, used alongside usual Parkinson's medications like levodopa rather than replacing them. The trial is looking for adults 18 and older with Parkinson's at Hoehn and Yahr stage I to III who have camptocormia (≥30°) or Pisa syndrome (≥10°) and an MMSE over 23, excluding those with atypical parkinsonism, prior spinal surgery or major spinal disease, other neurological conditions, or severe dyskinesias.
Locations
- IRCCS Mondino Foundation, Pavullo nel Frignano, Pavia, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Neurorehabilitation. The goal is to reduce abnormal forward or sideways bending of the trunk, namely camptocormia and Pisa syndrome, to improve posture, balance and daily function in people with Parkinson's. The approach uses an AI-guided home neurorehabilitation program that tracks trunk angles with sensors or camera-based analysis, gives real-time feedback, and personalizes strengthening, stretching and posture-training exercises, used alongside usual Parkinson's medications like levodopa rather than replacing them. The trial is looking for adults 18 and older with Parkinson's at Hoehn and Yahr stage I to III who have camptocormia (≥30°) or Pisa syndrome (≥10°) and an MMSE over 23, excluding those with atypical parkinsonism, prior spinal surgery or major spinal disease, other neurological conditions, or severe dyskinesias.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 3 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.